Kurser indlĂŠses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
- EuropÀische Aktien
u user_ce10af IV i Schnack
0 13 - TR - Probleme beim login in die Web App
Jens V i Schnack0 21
Nyheder Til nyhedsfeedet
Coloplast A-S announces quarterly results for 03.11.2026
Coloplast A-S will release results on 03.11.2026 for the quarter ended 30.09.2026. Eleven analysts on average estimate EPS for the quarter at 5.91 DKK versus 3.88 DKK a year earlier, and 15 analysts forecast revenue of 7.40 bn DKK versus 6.96 bn DKK in the year-ago quarter. For the most recently completed fiscal year, 22 analysts predict EPS of 25.45 DKK (prev. year 16.13 DKK) and 23 analysts expect annual revenue of 28.88 bn DKK (prev. year 27.87 bn DKK). » Mere pÄ finanzen.net
Coloplast A-S expects slight revenue growth and higher EPS for Q3, results on Nov. 3
Coloplast A-S will release results for the quarter ended Sept. 30 on Nov. 3. Ten analysts see an average EPS of USD 0.090 versus USD 0.060 a year earlier. Quarterly revenues are forecast on average at USD 1.12 billion (+2.6% year-on-year). For the past fiscal year analysts on average expect EPS of USD 0.385 and revenue of USD 4.38 billion. » Mere pÄ finanzen.net
Coloplast share falls after downgrade by JPMorgan
Coloplastâs share dropped 3.3% and fell intraday to as low as 427.8 DKK after JPMorgan cut its rating from "Neutral" to "Underweight" and lowered the December 2027 price target from 484 DKK to 377 DKK (about â22%). The bank cited a high P/E ratio of 35.35 and a valuation premium of roughly 20% versus the medtech sector, while earnings growth lags the industry. JPMorgan also noted governance uncertainty and expects the new CEO is likely to revise midâterm financial targets down when results are presented on 3 November; weak Q3 margins and increased short interest add further pressure. » Mere pĂ„ de.investing.com
Coloplast A-S (B) announces quarterly results for period to 30 June 2026
Coloplast A-S (B) will present the numbers for the quarter to 30 June 2026 on 18 August 2026. Ten analysts expect on average an EPS of 6.08 DKK versus 3.57 DKK in the prior year. Fourteen analysts forecast revenue of on average 7.26 billion DKK, an increase of 4.34% versus the year-earlier quarter. For the current fiscal year, consensus estimates are 24.88 DKK earnings per share and 28.79 billion DKK revenue. » Mere pÄ finanzen.net
Coloplast A-S (spons ADRs) announces quarterly results for June 30, 2026
Coloplast A-S (spons ADRs) will present results for the quarter ended June 30, 2026 on August 18, 2026. Nine analysts expect EPS of on average $0.093 (prior year $0.050); 13 analysts forecast revenue of about $1.11 billion (up 5.4% from $1.06 billion). For the current fiscal year, consensus estimates are $0.382 EPS and $4.43 billion in revenue (prior year: $0.240 / $4.12 billion). » Mere pÄ finanzen.net
Historisk udbytte Udbytte
Alle nĂžgletal for udbytte Alle nĂžgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| OmsĂŠtning | 7,44Â mia. | 105,80Â % |
| Bruttofortjeneste | 4,87Â mia. | 24,73Â % |
| Nettoresultat | 1,18Â mia. | 35,56Â % |
| EBITDA | 2,1Â mia. | 106,10Â % |
Fundamentale data
| NĂžgletal | VĂŠrdi |
|---|---|
MarkedsvÊrdi | 14,88 mia. ⏠|
Antal aktier | 225,37Â mio. |
HÞjeste/laveste i 52 uger | 86,62 ⏠- 49,48 ⏠|
Udbytteafkast | 4,64Â % |
Udbytte TTM | 3,08 ⏠|
Beta | 0,55 |
P/E (PE Ratio) | 36,08 |
PEG (PEG Ratio) | -2,34 |
K/I (PB Ratio) | 7,76 |
P/S (PS Ratio) | 3,83 |
Virksomhedsprofil
Coloplast A/S udvikler, fremstiller og markedsfÞrer medicinske produkter. Virksomheden er engageret i udvikling, markedsfÞring og salg af produkter og services til intim sundhedspleje, rettet mod personer med sygdomme af privat og personlig karakter. Dens aktiviteter er opdelt i fire forretningsomrÄder: Ostomy Care, som tilbyder produkter til personer, hvis tarmudgang er blevet flyttet gennem bugvÊggen; Continence Care, som tilbyder produkter til personer med sygdomme i og skader pÄ urinsystemet; Urology Care, som tilbyder produkter til personer med sygdomme i og skader pÄ nyrerne, urinsystemet eller det mandlige reproduktionssystem; og Wound & Skin Care til behandling af kroniske sÄr og hudplejeprodukter til forebyggelse og behandling. Virksomheden leverer produkter til hospitaler, institutioner samt grossister og apoteker.
| Navn | COLOPLAST |
| CEO | Gavin Wood |
| Hjemsted | HumlebĂŠk,
ze Danmark |
| Websted | |
| Sektor | Sundhed |
| Branche | Sundhedsudstyr og -produkter |
| BĂžrsnotering | 24.01.2007 |
| Medarbejdere | 17.524 |
Tickersymboler
| BĂžrs | Symbol |
|---|---|
XETRA | CBHD.DE |
Pnk | CLPBF |
Nasdaq Copenhagen | COLO-B.CO |
Copenhagen | COLO B.CO |
Frankfurt | CBHD.F |
DĂŒsseldorf | CBHD.DU |
London | 0QBO.L |
SIX | COLOB.SW |
MĂŒnchen | CBHD.MU |
Wien | COLO.VI |